A Phase 1b/2 Study of the PARP Inhibitor Niraparib in Combination With Trastuzumab in Patients With Metastatic HER2+ Breast Cancer
Latest Information Update: 16 Dec 2022
At a glance
- Drugs Niraparib (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Dec 2022 Planned End Date changed from 30 Dec 2023 to 30 Dec 2024.
- 13 Dec 2022 Planned primary completion date changed from 1 Nov 2022 to 1 Nov 2024.
- 09 Nov 2022 Planned End Date changed from 1 Nov 2022 to 30 Dec 2023.